Shanghai Laisi (002252.SZ): SR604 injection solution's application for new clinical trial indications has been accepted.

Zhitong Finance APP News, Shanghai RAAS (002252.SZ) announced that the company recently received a "Acceptance Notice" issued by the National Medical Products Administration, approving the company's application to conduct clinical trials for the indication of "prevention and treatment of bleeding in patients with vascular hemophilia" for SR604 injection. SR604 injection is a humanized high-affinity human activated protein C fusion protein, a monoclonal antibody preparation that specifically inhibits the anticoagulant function of human activated protein C.